Crossmark

Guiding syringe selection for intravitreal injections: injectability and stability analysis of compounded pegcetacoplan (SYFOVRE) and the broader implications for high-viscosity ophthalmic therapies

Crossref DOI link: https://doi.org/10.1186/s40942-026-00832-3

Published Online: 2026-03-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Felfeli, Tina

Lane, Natalie M.

Mandelcorn, Efrem D.
License Information

Text and Data Mining valid from 2026-03-12

Version of Record valid from 2026-04-21
More Information

Article History

Received: 22 November 2025

Accepted: 2 March 2026

First Online: 12 March 2026

Declarations

:

: This study was reviewed and approved by the University Health Network Ethics Review Board (23-6021).

: Pegcetacoplan (SYFOVRE), the first FDA-approved therapy for dry AMD supplied only in vial format, requires careful syringe selection due to its high viscosity. In this study, stability was preserved across syringe types, but injectability and particulate burden varied. Ophthalmic-specific syringes, especially Zero Residual and StaClear, outperformed conventional syringes, supporting safer, more efficient intravitreal delivery.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below